Please ensure Javascript is enabled for purposes of website accessibility

These 2 Shocking Stocks Have Outperformed the S&P in 2020 -- by a Lot

By George Budwell - Aug 31, 2020 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are these two COVID-19 vaccine stocks still worth buying?

Despite a rough start to the year due to COVID-19, the S&P 500 has bounced back nicely since hitting a low point in March. In fact, this closely watched stock index is currently up by a respectable 8.6% for the year. 

The S&P 500's fairly strong performance in 2020, however, is nothing compared to that of the clinical-stage biotechs Novavax (NVAX -2.68%) and Vaxart (VXRT 5.12%). At one point this year, Novavax's shares were up by an astonishing 4,500%, and Vaxart's stock jumped by a rip-roaring 4,680% at its high-water mark in 2020.

Image of a bandage on a person's upper arm.

Image source: Getty Images.

Although these two coronavirus vaccine stocks have pulled back significantly from their 52-week highs, Novavax and Vaxart are still crushing the S&P 500 from a share price performance standpoint. Should bargain hunters take advantage of this recent downward trend in these top growth stocks, or is it best to keep a safe distance? Let's dig deeper to find out. 

Can Novavax rebound after a disappointing August?

Novavax's meteoric rise this year has been powered mainly by its recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373. This experimental vaccine grabbed Wall Street's attention this year for two reasons:

  1. Novavax secured roughly $2 billion in funding from the Coalition for Epidemic Preparedness Innovations, the Department of Defense, and Operation Warp Speed (OWS) to accelerate the vaccine's development. That's a huge chunk of change for a company that started the year off with a market cap of $145 million.
  2. NVX-CoV2373's phase 1 trial results were impressive enough that some analysts argued this vaccine might turn out to be the best of the bunch. So, despite Novavax's late-comer status to the COVID-19 vaccine game, the company may still end up earning a sizable portion of the market when everything is said and done. 

What's the verdict? Investors may want to hold their horses when it comes to buying this biotech stock. The COVID-19 vaccine landscape remains extremely fluid at this stage. What's more, Novavax's candidate won't post interim phase 2 results until later this year.

That's a lot of uncertainty -- and Wall Street hates uncertainty. In other words, Novavax's stock probably won't reverse course until more data points -- for both its vaccine as well as the other leaders in the space -- are public knowledge.  

Has Vaxart lost its mojo? 

Vaxart's main selling point to investors is its novel oral vaccine platform. The biotech's shares rocketed higher back in June in response to the news that its oral COVID-19 vaccine had been selected to participate in a non-human primate challenge study by the government's OWS program.

Some investors, though, apparently took this news to mean that Vaxart had also received significant financial support from OWS to accelerate the development of its oral COVID-19 vaccine. That was never the case. As a result, the biotech's shares have since dropped by a whopping 63% from their former highs in less than two months' time. Vaxart is also facing a class action lawsuit over this funding-related mixup.

Is it time to buy this falling knife? Vaxart's oral vaccine approach could have major logistical and clinical advantages over injectable vaccines. Moreover, the company is poised to initiate the first human trial for this unique COVID-19 vaccine contender within the next few months. So there are some solid reasons for investors to at least consider buying this small-cap biotech stock right now.     

Having said that, Vaxart clearly isn't a stock for conservative investors. It could take years to gain a regulatory approval for an oral COVID-19 vaccine. By then, the opportunity may have evaporated due to the approval of more traditional vaccines. 

Bottom line: There are simply too many unknowns when it comes to Vaxart and its oral vaccine for COVID-19. Therefore, investors might be wise to wait until this story matures a bit more before buying shares.   

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$60.27 (-2.68%) $-1.66
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$4.11 (5.12%) $0.20
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,145.19 (-0.16%) $-6.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.